Company Overview of Aerovance, Inc.
Aerovance, Inc. develops and commercializes medicines for respiratory and allergic diseases. The company offers Aerovant, a novel molecule that targets the root cause of asthma by blocking Th2 allergic inflammation; Aeroderm, which is formulated for the treatment of atopic eczema; Aerolytic that is used for the treatment of cystic fibrosis; and Pulmolytic, which is used for the treatment of chronic obstructive pulmonary disease. Aerovance, Inc. was founded in 2004 and is based in Berkeley, California.
2929 7th Street
Berkeley, CA 94710
Founded in 2004
Key Executives for Aerovance, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Aerovance, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.